Compare AMPY & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMPY | VYGR |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 215.9M | 203.6M |
| IPO Year | 2011 | 2015 |
| Metric | AMPY | VYGR |
|---|---|---|
| Price | $3.79 | $3.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | 620.9K | ★ 750.5K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 232.26 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $208,637,000.00 | $10,135,000.00 |
| Revenue This Year | N/A | $34.04 |
| Revenue Next Year | $23.83 | $7.92 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.41 | $2.88 |
| 52 Week High | $6.79 | $5.55 |
| Indicator | AMPY | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 36.80 | 36.64 |
| Support Level | N/A | $2.96 |
| Resistance Level | $4.23 | $4.33 |
| Average True Range (ATR) | 0.15 | 0.18 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 19.44 | 10.71 |
Amplify Energy Corp is an independent oil and natural gas company engaged in the acquisition, development, exploitation, and production of oil and natural gas properties in the United States. The companies oil and natural gas properties are located in large, mature oil and natural gas reservoirs. The company assets consists of producing oil and natural gas properties located in Oklahoma, the Rockies, federal waters offshore Southern California, East Texas/North Louisiana and Eagle Ford.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.